Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

  • End date
    May 23, 2022
  • participants needed
  • sponsor
    Asclepius Technology Company Group (Suzhou) Co., Ltd.
Updated on 23 January 2021
refractory multiple myeloma


The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, multiple myeloma (mm)
Treatment BCMA CAR-NK 92 cells
Clinical Study IdentifierNCT03940833
SponsorAsclepius Technology Company Group (Suzhou) Co., Ltd.
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

18 years to 80 years, expected survival > 3 months
Confirmed diagnosis of active MM as defined by IMWG. BCMA expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry
BCMA-expressing B cell malignancy must be assured and must be relapsed or refractory disease
ECOG performance status of 0 - 1
Cardiac function: 1 - 2 levels; Liver: TBIL 3ULNAST 2.5 ULNALT 2.5ULN; kidney: Cr 1.25ULN
No serious allergic constitution
No other serous diseases that conflicts with the clinical program
No other cancer history
Female participants of reproductive potential must have a negative serum pregnancy test
Subjects must have signed written, informed consent

Exclusion Criteria

Pregnant or lactating women
Uncontrolled active infection, HIV infection, syphilis serology reaction positive
Active hepatitis B or hepatitis C infection
Recent or current use of glucocorticoid or other immunosuppressor
Serious mental disorder
With severe cardiac, liver, renal insufficiency, diabetes and other diseases
Participate in other clinical research in the past three months
Previously treatment with any gene therapy products
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note